Priya Kulkarni

Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers

Jeremy J. Lim, Rong Deng, Michael A. Derby et al. · Antimicrobial Agents and Chemotherapy · 2016 · 49 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Comparative efficacy of four Ayurvedic formulations in the treatment of acne vulgaris: a double-blind randomised placebo-controlled clinical evaluation

Prakash Paranjpe, Priya Kulkarni · Journal of Ethnopharmacology · 1995 · 42 citations

Medicine, Dermatology, Clinical Pharmacology +6

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection

Jeremy J. Lim, Anna Nilsson, Michael Silverman et al. · Antimicrobial Agents and Chemotherapy · 2020 · 41 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +12

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection

Jeremy J. Lim, Sadia Dar, Dirk Venter et al. · Open Forum Infectious Diseases · 2021 · 16 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +17

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers

Jeremy J. Lim, Michael A. Derby, Yaping Zhang et al. · Antimicrobial Agents and Chemotherapy · 2017 · 12 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16